Ardelyx, Inc.

Ardelyx President and CEO Michael Raab sold 41,666 shares worth approximately $243,000 on March 16, 2026, as part of a routine 10b5-1 trading plan. The sale represented 2.21% of his holdings and followed an option exercise. Despite recent legal headwinds abating and a new chief medical officer appointment, the stock is down 16.57% over five years...

Ardelyx, Inc. announced the appointment of Dr. Rajani Dinavahi as Chief Medical Officer. Dr. Dinavahi brings over two decades of healthcare and biotechnology experience, including leadership roles at Atara Biotherapeutics and Amgen. She will lead medical capabilities and pipeline advancement for the commercial-stage biopharmaceutical company.

Ardelyx, Inc. announced it will hold a conference call on February 19, 2026, to discuss full year and fourth quarter 2025 financial results and provide a business update. The call will feature commentary from executive leadership including CEO Mike Raab and CFO Sue Hohenleitner. The company has two FDA-approved commercial products (IBSRELA and XP...

The biotech sector is experiencing significant growth driven by FDA regulatory shifts favoring advanced cell and gene therapies. Companies like Avant Technologies, MannKind, Vertex Pharmaceuticals, Fate Therapeutics, and Ardelyx are positioned to benefit from a projected $88.85 billion next-gen treatment market by 2030 and $9.06 trillion biotech ...

Cable One reported disappointing Q1 2025 earnings, missing analyst expectations and suspending its dividend. The stock price fell over 40% on this news, leading Pomerantz LLP to investigate potential securities fraud or other unlawful business practices by the company and its officers/directors.